Practice
Featured experience
Novo Nordisk proposed $9.1 billion acquisition of Metsera
We are advising Novo Nordisk on the transaction
HNI $2.2 billion acquisition of Steelcase
We are advising HNI on the transaction
Amer Sports $1.3 billion secondary offering
We advised Amer Sports on its SEC-registered secondary offering of ordinary shares
Cintas $5.3 billion proposal to acquire UniFirst
We are advising Cintas on the proposed acquisition
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Intra-Cellular Therapies $14.6 billion acquisition by Johnson & Johnson
We are advising Intra-Cellular Therapies on the transaction
Baldwin Group $935 million credit facilities financing
We advised the borrower on the refinancing and amendment
Royalty Pharma $1.1 billion acquisition of its external manager and $3 billion share repurchase
We are advising Royalty Pharma on the transaction
Cintas $5.3 billion proposal to acquire UniFirst
We are advising Cintas on the proposed acquisition
Teoxane proposal to acquire Revance Therapeutics
We are advising Teoxane on the proposed acquisition
Paychex $4.1 billion acquisition of Paycor HCM
We are advising Paychex on the transaction
Precigen $79 million preferred stock and warrants offering
We advised Precigen on the private placement
VersaBank $75 million follow-on offering
The common shares are dual-listed on the Nasdaq Global Select Market and the Toronto Stock Exchange
Hertz $500 million senior notes offering and concurrent consent solicitations
We advised Hertz on the transactions